Ward, FrankKennedy, Paul TAl-Fatyan, Farah MuthannaDahal, Lekh NathAbu Eid, Rasha2025-07-112025-07-112025Ward, F, Kennedy, P T, Al-Fatyan, F M, Dahal, L N & Abu Eid, R 2025, 'CTLA-4 – two pathways to anti-tumour immunity?', Immunotherapy Advances, vol. 5, no. 1, ltaf008. https://doi.org/10.1093/immadv/ltaf0082732-4303https://hdl.handle.net/2164/25689Open Access via the Oxford University Press agreement Acknowledgements The Editor-in-Chief, Tim Elliott, and handling editor, Jeanette Leusen, would like to thank reviewers, Simon Milling and an anonymous reviewer, for their contribution to the publication of this article.101093031engSDG 3 - Good Health and Well-beingimmune checkpoint inhibitorsCTLA-4regulatory T cells (Treg)soluble CTLA-4 (sCTLA-4)RC0254 Neoplasms. Tumors. Oncology (including Cancer)Supplementary DataDASRC0254Journal item10.1093/immadv/ltaf00851